Global Non-Invasive Prenatal Testing Market (2021 to 2028) – Share, Size, Trends and Industry Analysis Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Non-Invasive Prenatal Testing Market Share, Size, Trends, Industry Analysis Report, By Gestation Period; By Component; By Method; By Application; By End-Use; By Regions; Segment Forecast, 2021 – 2028” report has been added to ResearchAndMarkets.com’s offering.

The global non-invasive prenatal testing (NIPT) market size is expected to reach USD 6.56 billion by 2028 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.

The market demand for non-invasive prenatal testing is expected to increase during the forecast period owing to growth in the occurrence of genetic disorders, increasing awareness regarding early fetal testing, and advancing maternal age. The significant market growth in healthcare infrastructure, technological advancements, and favorable regulations are some factors expected to provide growth opportunities during the forecast period.

The gestation period segment has been divided into 0-12 weeks, 13-24 weeks, 25-36 weeks. Testing performed for 13 – 24 weeks involves blood tests and ultrasound to detect genetic disorders and neural tube defects. Ultrasounds are also used in this period to examine the anatomy and associated disorders. There has been a high demand for consumables required during non-invasive prenatal testing. The rising awareness regarding fetal testing, coupled with technological advancements, supportive government regulations, and advanced healthcare infrastructure boosts the market growth.

Non-invasive prenatal testing is used for the detection of Monosomy, Trisomy, Microdeletion Syndrome, and Others. The trisomy accounted for a major share of the global market for non-invasive prenatal testing owing to high accuracy in detection of trisomy, growing maternal age, and increasing awareness regarding early and non-invasive fetal diagnosis. The test for detection of trisomy is performed after 10 weeks for enhanced safety, reliability, and accuracy for detection of the three common trisomy including chromosomes 21, 18, and 13.

The different methods of non-invasive prenatal testing include cell-free DNA in maternal plasma tests, ultrasound detection, biochemical screening tests, and others. The cell-free DNA in the maternal plasma segment is expected to grow significantly during the forecast period. The increasing accuracy in the detection of chromosomal abnormalities through this method, growing patient awareness, and efficient planning for pregnancy management are some factors driving the growth of this segment.

Non-invasive prenatal testing services are offered in diagnostic centers, hospitals, clinics, and others. The diagnostic centers segment accounted for the highest share in 2020. The increasing occurrence of chromosomal abnormalities coupled with supportive government initiatives supports the growth of this segment. The presence of specialized equipment, advanced healthcare infrastructure, and expert professionals further encourage patients to visit diagnostic centers.

North America dominated the global NIPT market in 2020 and is expected to maintain its dominance over the forecast period. High living standards, significant investment in healthcare services, and increasing occurrence of chromosome abnormalities support market growth in this region. However, Asia-Pacific is expected to exhibit significant growth during the forecast period. Increasing population coupled with increasing awareness regarding fetal testing fuels growth in this region. Leading global players are expanding their presence in developing nations of China, Japan, India, and South Korea to tap the growth opportunities offered by these countries.

On account of the technological advancements, and greater need to cater to customer requirements, companies are collaborating in order to strengthen the market presence and gain market share. Broadening of the product portfolio is another trend that is visible in the industry.

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. Non-Invasive Prenatal Testing (NIPT) Market Insights

4.1. Non-Invasive Prenatal Testing (NIPT) – Industry snapshot

4.2. Non-Invasive Prenatal Testing (NIPT) Market Dynamics

4.3. Porter’s Five Forces Analysis

4.4. PESTLE Analysis

4.5. Non-Invasive Prenatal Testing (NIPT) Market Industry trends

5. Non-Invasive Prenatal Testing (NIPT) Market Assessment by Gestation Period

5.1. Key Findings

5.2. Introduction

5.3. 0-12 weeks

5.4. 13-24 weeks

5.5. 25-36 weeks

6. Global Non-Invasive Prenatal Testing (NIPT) Market, by Component

6.1. Key Findings

6.2. Introduction

6.3. Consumables

6.4. Instruments

6.5. Software

6.6. Services

7. Global Non-Invasive Prenatal Testing (NIPT) Market, by Application

7.1. Key Findings

7.2. Introduction

7.3. Monosomy

7.4. Trisomy

7.5. Microdeletion Syndrome

7.6. Others

8. Non-Invasive Prenatal Testing (NIPT) Market Assessment by Method

8.1. Key Findings

8.2. Introduction

8.3. Cell-Free DNA in Maternal Plasma Tests

8.4. Ultrasound Detection

8.5. Biochemical Screening Tests

8.6. Others

9. Global Non-Invasive Prenatal Testing (NIPT) Market, by End-Use

9.1. Key Findings

9.2. Introduction

9.3. Diagnostic Centers

9.4. Hospitals

9.5. Clinics

9.6. Others

10. Non-Invasive Prenatal Testing (NIPT) Market Assessment by Geography

10.1. Key findings

10.2. Introduction

10.3. Non-Invasive Prenatal Testing (NIPT) Market – North America

10.4. Non-Invasive Prenatal Testing (NIPT) Market – Europe

10.5. Non-Invasive Prenatal Testing (NIPT) Market – Asia-Pacific

10.6. Non-Invasive Prenatal Testing (NIPT) Market – Middle East & Africa

10.7. Non-Invasive Prenatal Testing (NIPT) Market – Latin America

11. Competitive Landscape

11.1. Expansion and Acquisition Analysis

11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

12.1. Agilent Technologies, Inc.

12.2. Laboratory Corporation of America Holdings

12.3. Illumina, Inc.

12.4. F. Hoffman-La Roche Ltd.

12.5. Yourgene Health

12.6. Perkinelmer, Inc.

12.7. GE Healthcare

12.8. Quest Diagnostics

12.9. Thermo Fisher Scientific, Inc.

12.10. Sequenom

For more information about this report visit https://www.researchandmarkets.com/r/to1qk3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900